A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours

British Journal of Cancer

Volumn 83, Issue 1, 2000, Pages 22-29

  Pronk, L C ^a,d,e   Vasey, P ^b,d   Sparreboom, A ^a,d   Reigner, B ^c,d   Planting, A S Th ^a,d   Gordon, R J ^c,d   Osterwalder, B ^c,d   Verweij, J ^a,d   Twelves, C ^b,d  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^c IQVIA   (United States)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Capecitabine; Docetaxel; Pharmacokinetics; Phase I

Indexed keywords

CAPECITABINE; DEXAMETHASONE; DOCETAXEL; METHYLPREDNISOLONE;

ADULT; AGED; ALLERGY; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG ELIMINATION; DRUG HALF LIFE; EDEMA; FEMALE; FEVER; HUMAN; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; VOMITING;

EID: 0034079455     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1160     Document Type: Article

References (40)

1. Aamdal S, Wolff I, Kaplan S, Paridaens R, Kerger R, Schachter J, Wanders J, Franklin H and Verweij J (1994) Taxotere in advanced malignant melanoma: a phase II trial of the EORTC Clinical Trials Group. Eur J Cancer 30A: 1061-1064
2. Aapro MS, Zulian G, Alberto P, Bruno R, Oulid Aissa D and Le Bail N (1992) Phase I and pharmacokinetic study of RP 56976 in a new ethanol-free formulation of Taxotere. Ann Oncol 3 (suppl 5): 208
3. Bisset D, Setanoians A, Cassidy J, Graham MA, Chadwick GA, Wilson P, Auzannet V, Le Bail N, Kaye SB and Kerr DJ (1993) Phase I and pharmacokinetic study of Taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 53: 523-527
4. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown C and Griffin T (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17: 485-493
5. Ten Bokkel-Huinink WW, Prove AM, Piccart M, Steward W, Tursz T, Wanders J, Franklin H, Clavel M, Verweij J, Alaki M, Bayssas M and Kaye SB (1994) A phase II trial with docetaxel (Taxotere) in second-line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol 5: 527-532
6. Brundage MD, Pater JL and Zee B (1993) Assessing the reliability of two toxicity scales: implications for interpretating toxicity data. J Natl Cancer Inst 85: 1138-1148
7. Bruno R and Sanderink GJ (1993) Pharmacokinetics and metabolism of Taxotere. In: Pharmacokinetics and Cancer Chemotherapy, Workman P and Graham MA (eds), pp. 305-313, Cold Spring Harbor Laboratory: New York, NY
8. Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, Behr J, Gordon RJ, Osterwalder B and Griffin T (1998) Preliminary results of a novel oral fluoropyrimidine carbamate. J Clin Oncol 16: 1795-1802
9. Burris H, Irvin R, Kuhn J, Kalter S, Smith L, Shaffer D, Fields S, Weiss G, Eckardt J, Rodriguez G, Rinaldi D, Wall J, Cook G, Smith S, Vreeland F, Bayssas M, Le Bail N and Von Hoff D (1993) Phase I clinical trial of Taxotere administered as either a 2-hour or 6-hour intravenous infusion every 3 weeks. J Clin Oncol 11: 950-958
10. Catimel G, Verweij J, Mattijsen V, Hanauske A, Piccart M, Wanders J, Franklin H, Le Bail N, Clavel M and Kaye SB (1994) Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5: 533-537
11. Cerny T, Kaplan S, Pavlidis N, Schöffski P, Epelbaum R, Van Meerbeek J, Wanders J, Franklin HR and Kaye S (1994) Docetaxel (Taxotere) is active in non-small cell lung cancer: a phase II trial of the EORTC Clinical Trials Group. Br J Cancer 70: 384-387
12. Chevallier B, Fumoleau P, Kerbrat P, Dieras V, roche H, Krakowski I, Azli N, Bayssas M, Lentz MA and van Glabbeke M (1995) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13: 314-322
13. Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N and Marty M (1993) Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 53: 1037-1042
14. Findlay M, Van Cutsem E, Kocha W, Allman D, Laffranchi B, Griffin T, Osterwalder B, Dalley D, Pazdur R and Verweij J (1997) A randomized phase II study of Xeloda (Capecitabine) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 16: 227a (abstract 798)
15. De Forni M, Rougier P, Adenis A, Ducreux M, Djazouli K, Adams D, Clouel P, Blanc C, Bayssas M, Bonneterre J and Armand JP (1994) Phase II study of Taxotere in locally advanced and/or metastatic pancreatic cancer. Ann Oncol 5 (suppl 5): 509
16. Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R, Murphy WK, Lippman S, Benner S, Glisson B, Chasen M, Ki Hong W and Raber M (1995) Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer. J Clin Oncol 13: 645-651
17. Gueritte-Voegelein F, Guenard D, Lavelle F, Le Goff MT, Mangatal L and Poitier P (1991) Relationships between the structure of Taxol analogues and their antimitotic activity. J Med Chem 34: 992-998
18. Hilkens PHE, Verweij J, Stoter G, Vecht Ch, Van Putten WLJ and van den Bent MJ (1996) Peripheral neurotoxicity induced by docetaxel. Neurology 46: 104-108
19. Investigational drug brochure: Capecitabine (Ro 09-1978) Fourth Version. December 1997
20. Van Hoesel QGCM, Verweij J, Catimel G, Clavel M, Kerbrat P, van Oosterom AT, Kerger J, Tursz T, van Glabbeke M, Van Pottelsberghe C, Le Bail N, Mouridsen H, for the EORTC Soft Tissue and Bone Sarcoma Group (1994) Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. Ann Oncol 5: 539-542
21. Ishikawa T, Sawada N, Sekiguchi F, Fukase Y and Ishitsuka H (1997) Xeloda™ (Capecitabine), a new oral fluoropyrimidine carbamate with an improved efficacy profile over other fluoropyrimidines. Proc Am Soc Clin Oncol 16: 226a (abstract 796)
22. Khoury P, Villalona-Calero M, Blum J, Diab S, Elledge R, Kraynak M, Moczygemba J, Kromelis P, Morales I, Brown C, Griffin T, Von Hoff D and Rowinsky E (1998) Phase I study of capecitabine in combination with paclitaxel in patients with previously treated metastatic breast cancer. Proc Am Soc Clin Oncol 17: 206a (abstract 793)
23. Loos WJ, Verweij J, Nooter K, Stoter G and Sparreboom A (1997) Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed phase high-performance liquid chromatography. J Chromatogr B 693: 437-441
24. Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, Reigner B, Griffin T, Kaye S and Verweij J (1998) Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 16: 2977-2985
25. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small-cell lung cancer. Cancer 75: 968-972
26. O'Shaugnessy J, Moiseyenko V, Bell D, Nabholtz JM, Miles D, Gorbunova V, Laws S, Griffin T and Osterwalder B (1998) A randomised phase II study of Xeloda (Capecitabine) vs CMF as first-line chemotherapy of breast cancer in women > 55 years. Proc Am Soc Clin Oncol 17: 103a (abstract 398)
27. Pazdur R, Newman RA, Newman BM, Fuentes A, Benvenuto J, Bready B, Moore D, Jaiyesimi I, Vreeland F, Bayssas MMG and Raber MN (1992) Phase I trial of Taxotere: 5-day schedule. J Natl Cancer Inst 84: 1781-1788
28. Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, Bontenbal M, Awada A, Selleslags J, Van Vreckem A and Van Glabbeke M (1997) Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer investigational drug branch for breast cancer. J Clin Oncol 15: 3149-3155
29. Pronk LC, Stoter G and Verweij J (1995) Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side effects. Cancer Treatment Rev 21: 463-478
30. Reigner B, Clive S, Cassidy J, Jodrell D, Schulz R, Goggin T, Banken L, Roos B, Utoh M, Mulligan T and Weidekamm E (1999) Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients. Cancer Chemother Pharmacol (in press)
31. Ringel I and Horwitz SB (1991) Studies with RP 56976 (Taxotere): a semisynthetic analog of Taxol. J Natl Cancer Inst 83: 288-291
32. Rowinsky EK and Donehower RC (1991) The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmac Ther 52: 35-84
33. Rowland M and Tozer TN (1995) Clinical pharmacokinetics: concepts and applications, 3rd Edition. Media, Williams and Wilkins
34. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T and Ishitsuka H (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res 4: 1013-1019
35. Schrijvers D, Wanders J, Dirix L, Prove A, Vonck I, Van Oosterom AT and Kaye S (1993) Coping with toxicities of docetaxel (Taxotere). Ann Oncol 4: 610-611
36. Sulkes A, Smyth J, Sessa C, van Oosterom AT, Vermorken J, Kaye SB, Le Bail N, Verweij J, for the EORTC Early Clinical Studies Group (1994) Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer 70: 380-383
37. Taguchi T, Ishitani K, Saitoh K, Kurihara M, Tominaga T, Fukuyama Y, Saigenji K, Toge T, Takashima S, Sugimachi K and Hara Y (1996) A Japanese phase I study of continuous twice daily treatment with capecitabine in patients with advanced and/or metastatic solid tumors. Ann Oncol 7: 87 (abstract 299)
38. Tomiak E, Piccart MJ, Kerger J, Lips S, Awada A, de Valeriola D, Ravoet C, Lossignol D, Sculier JP, Auzannet V, Le Bail N, Bayssas M and Klastersky J (1993) Phase I study of Taxotere (RP 56976, NSC 628503) administered as a one hour intravenous infusion on a weekly basis. J Clin Oncol 12: 1458-1467
39. Twelves C, Budman DR, Creaven PJ, Schellens JHM, Kuruma I, Dumont E, Osterwalder B and Reigner BG (1996) Pharmacokinetics (PK) and pharmacodynamics (PD) of capecitabine in two phase I studies. Proc Am Soc Clin Oncol 5: 476 (abstract 1509)
40. WHO (1979) Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication 48: 22-26